GET DAILY SIGNALSCompugen (CGEN) Analyst Consensus Suggests +133% Potential Upside from Current Levels
Key Takeaways
- The central target of $4.60 is the arithmetic mean of five verified analyst price targets, which range from $4.00 to $6.00.
- At a latest verified price near $1.97, reaching $4.60 would require a rise of roughly 133% — a very large move.
- Coverage skews bullish: the five firms tracked rate CGEN a "Strong Buy," with targets clustered between $4 and $6.
- Supporting factors include a strengthened cash runway into 2029, partnered immuno-oncology programs, and upcoming clinical readouts.
- Key risks include dependence on partner execution, lumpy milestone-driven revenue, and early-stage clinical uncertainty.
- For more detail, explore Major News, Today's Price Move, the Forecast, and Earnings pages for CGEN.
- Explore Trending AI Robots to see how AI-driven trading tools are screening stocks and ETFs.
Analyst Price Targets and Consensus View
Compugen Ltd. (CGEN) is a clinical-stage Israeli biotechnology company that applies its AI/ML-powered "Unigen" discovery platform to cancer immunotherapy. It is a stock, not an ETF, and it carries a small market capitalization of roughly $186 million. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Across five verified analyst price targets, the range runs from $4.00 to $6.00. The individual figures are $4.00 (HC Wainwright, Stifel, and Oppenheimer), $5.00 (Leerink Partners, which trimmed its target from $13 in May 2026), and $6.00 (Lake Street). The arithmetic mean is $4.60, which serves as the central target used throughout this article.
The views are uniformly constructive but differ on magnitude. Bulls point to Compugen's partnered pipeline and discovery engine, while the more cautious end of the range reflects the reality that revenue is milestone-driven and clinical outcomes remain uncertain. Leerink's decision to cut its target from $13 to $5 in May 2026 illustrates how sharply expectations can reset in early-stage biotech. Notably, no firm currently carries a Hold or Sell rating, so the target dispersion is narrower than the historical range, which earlier included figures above $13.
Current Market Position and Path Toward the Target
The latest verified closing price is about $1.97, with a 52-week range of roughly $1.43 to $3.24. Reaching the $4.60 central target implies upside of approximately 133% — by any standard, a very large move for a small-cap biotech, even one with an active clinical pipeline.
The path would likely depend less on quarterly revenue than on clinical and partnership milestones. Compugen's value rests on partnered assets including rilvegostomig (licensed to AstraZeneca) and GS-0321, plus its own early-stage programs. Because the company generates revenue mainly from collaboration and license agreements rather than product sales, the share price tends to respond to data readouts and partner progress rather than smooth operating results.
What Could Support a Move Toward the Target
- Strengthened balance sheet: Management has indicated a cash runway extending into 2029, reducing near-term dilution risk.
- Partner validation: AstraZeneca's continued development of rilvegostomig and encouraging partner-reported survival data reinforce the credibility of Compugen-originated targets.
- Upcoming catalysts: An interim readout from the MAIA study is expected in the first quarter of 2027, with royalty and milestone upside tied to partners such as AstraZeneca and Gilead.
- Discovery platform: The Unigen engine provides a potentially durable source of new immuno-oncology targets, supporting long-term pipeline renewal.
What Could Prevent the Target From Being Reached
- Partner dependency: Much of Compugen's potential value relies on external partners advancing programs, securing regulatory progress, and commercializing products. Delays or setbacks would defer milestones and royalties.
- Lumpy revenue: The sharp 2025 revenue inflection reflected collaboration and milestone income rather than a stable commercial trend, making future results hard to forecast.
- Clinical uncertainty: The MAIA study is small and exploratory, and a favorable readout may still require additional studies before any regulatory pathway is clear.
- Valuation compression risk: Micro-cap biotechs can re-rate quickly if sentiment toward the broader biotech sector or toward individual data events turns negative.
Technical Levels and Market Structure
CGEN trades just below the psychologically important $2.00 level. The 52-week low near $1.43, set in late 2025, is the most durable support area, while the 52-week high near $3.24 (April 2026) stands as the primary resistance zone. Any sustained move toward $4.60 would first need to reclaim and hold above the $3.24 prior high, a level roughly 64% above the current price, before approaching the analyst range. From what I see, the technical setup remains a key factor to monitor alongside fundamentals.
Time Horizon and What Investors Should Monitor
Analyst price targets generally reflect a research horizon of approximately 12 months, though specific horizons vary by firm. For CGEN, the most relevant near-term items include the next earnings report (expected around November 9, 2026), the MAIA interim readout expected in early 2027, any updates on rilvegostomig's development, and changes to partner milestones or analyst targets. Because the story is data-driven, clinical news and partnership announcements are likely to matter more than routine quarterly results.
Using AI Daily Buy/Sell Signals for CGEN
I rely on AI Daily Buy/Sell Signals to complement my fundamental work on names like this. The tool applies artificial intelligence to scan thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on technical behavior and market shifts. It helps me spot changes in trend more efficiently while keeping an eye on evolving conditions around clinical-stage biotechs.
Final Assessment
The $4.60 central target is the average of five verified analyst price targets ranging from $4.00 to $6.00, and it sits roughly 133% above the latest verified price near $1.97 — a very large required move. Support for the target comes from a strengthened cash position, validated partnered programs, and upcoming clinical catalysts, while the principal obstacles are partner dependence, milestone-driven revenue volatility, and early-stage clinical risk. The spread between a $4.00 low and a $6.00 high shows genuine disagreement about how richly the pipeline should be valued. Whether CGEN reaches $4.60 will likely hinge on the MAIA readout, partner execution, and broader biotech sentiment rather than any single quarter's results.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CGEN's RSI Oscillator recovers from oversold territory
The RSI Indicator for CGEN moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 37 of the 43 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +9.18% 3-day Advance, the price is estimated to grow further. Considering data from situations where CGEN advanced for three days, in 190 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
CGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for CGEN turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 39 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
CGEN moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CGEN crossed bearishly below the 50-day moving average on September 23, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CGEN entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 20 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 57 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating steady price growth. CGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.103) is normal, around the industry mean (3.037). P/E Ratio (5.184) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (3.083) is also within normal values, averaging (439.237).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of drug and diagnostics
Industry Biotechnology
Advertisement